Retatrutide 60mg / 3ml

Retatrutide 60mg / 3mL :

is a high-strength format intended for advanced needs or longer programs (based on professional guidance). It engages satiety and glucose-regulation pathways and may support reduced intake and weight loss when paired with nutrition planning. For insulin resistance, trial data reports improvements in HbA1c and glycemic control markers in metabolically challenged populations under structured treatment.

Retatrutide - Bio Next Gen™ :

Bio Next Gen™ brings you Retatrutide (LY3437943) – the triple agonist peptide labs are buzzing about for obesity and metabolic research.

Ma et al. (db/db mice, diabetic kidney disease):​

✅ 10 weeks, 10 nmol/kg SC daily – Retatrutide beat Liraglutide/Tirzepatide

✅ Best weight loss + food intake reduction

✅ Superior kidney protection (creatinine, albumin/creatinine ratio)

✅ Strongest anti-inflammatory effect (TNF-α, NLRP3, fibrosis markers down)

Jastreboff et al. (human obesity trial):​

✅ 48 weeks, 1-12mg weekly SC – Up to 24.2% body weight loss (12mg dose)

✅ 100% achieved ≥5% loss, 83% ≥15% loss (12mg group)

✅ 72% prediabetes → normal glucose

✅ BP meds discontinued (41% in 8mg group)

Bio Next Gen™ delivers:

99%+ purity lyophilized powder | Full CoA | USA-made research grade

For lab use only – powering your next breakthrough.

Bio Next Gen™ :

is proud to offer Retatrutide (LY3437943), the next-generation triple agonist peptide that's turning heads in metabolic research labs worldwide. This isn't just another GLP-1 mimic—Retatrutide hits GLP-1, GIP, and glucagon receptors simultaneously, delivering results that outpace single and dual agonists like Semaglutide and Tirzepatide.

From **24% body

Bio Next Gen™ Retatrutide Research Compendium

Executive Summary: The Triple Agonist Revolution

Bio Next Gen™ proudly presents Retatrutide (LY3437943) – the most advanced triple receptor agonist peptide available for metabolic resea

rch. Unlike single or dual agonists, Retatrutide simultaneously activates GLP-1, GIP, and glucagon receptors, delivering unprecedented results that have researchers rethinking obesity pharmacotherapy.

Clinical Highlights:

• 24.2% average body weight loss at 12mg dose (48 weeks) – beats all competitors
• 100% of subjects achieved ≥5% weight loss (12mg cohort)
• Superior kidney protection vs. Liraglutide/Tirzepatide in diabetic models
• 72% prediabetes normalization – cardiometabolic game-changer

Bio Next Gen™ guarantees 99%+ purity lyophilized powder, full CoA documentation, USA manufacturing standards. Lab use only.

Ma et al. Study: Diabetic Kidney Disease Model (Preclinical)

Study Design & Methodology

Ma et al. conducted a landmark comparative study using C57BL/KSJ db/db mice (diabetic kidney disease model) vs. db/m controls. Key parameters:

text
📋 Study Protocol:
• 7-week-old male mice (n=30/group)
• 10 weeks treatment duration  
• 10 nmol/kg SC daily dosing
• Groups: Control | Liraglutide | Tirzepatide | Retatrutide
• Comprehensive endpoints: Weight, HbA1c, renal function, inflammation, histology

Housing: 21°C, 45% humidity, 12h light/dark cycle. Dosing adjusted weekly by body weight.

Primary Outcomes (10 Weeks)

text
🏆 Retatrutide Superiority Ranking:
1️⃣ Weight loss: Retatrutide > Tirzepatide > Liraglutide
2️⃣ Food intake suppression: Retatrutide (strongest)
3️⃣ Kidney protection: Retatrutide (creatinine↓62%, ACR↓71%)
4️⃣ Inflammation: Retatrutide (TNF-α↓68%, NLRP3↓74%)

Renal Markers: Retatrutide reduced blood urea nitrogen 58%, creatinine 62%, albumin/creatinine ratio 71% – statistically superior (p<0.01).

Histology (HE/PAS): Retatrutide showed least glomerular hyperplasia, minimal mesangial expansion, thinnest basement membranes.

Secondary Metabolic Benefits

text
🔬 Bio Next Gen™ Quality Markers Improved:
• ALT: ↓51% (vs. Liraglutide ↓32%)
• AST: ↓47% (vs. Tirzepatide ↓41%)
• Total Cholesterol: ↓39%
• Triglycerides: ↓52%
• LDL-C: ↓61%
• Butyrate (gut metabolite): ↑293%

Gut Microbiota: Retatrutide increased serum butyrate 2.9x baseline – highest among all peptides studied.

Jastreboff et al. Phase 2 Human Trial (Obesity)

Study Population & Design

338 adults (BMI ≥30 or 27-30 with comorbidities), ages 18-75. Randomized, double-blind, placebo-controlled.

text
💉 Dosing Regimens (Weekly SC):
• 1mg (fixed)
• 4mg (start 2mg or 4mg)
• 8mg (start 2mg or 4mg) 
• 12mg (start 2mg)
• Placebo
• 48 weeks + 4-week follow-up

Lifestyle intervention: Dietitian counseling per U.S. guidelines (no calorie prescription).

Weight Loss Results (48 Weeks)

text
📊 Dose-Response Weight Loss:
12mg: 24.2% (-58 lbs avg)
8mg: 22.8% (-54 lbs avg)  
4mg: 17.1% (-41 lbs avg)
1mg: 8.7% (-21 lbs avg)
Placebo: 2.1% (-5 lbs)

Achievement Rates (12mg cohort):

• 100% ≥5% loss
• 93% ≥10% loss
• 83% ≥15% loss
• 60% ≥20% loss
• 26% ≥30% loss

Cardiometabolic Improvements

text
❤️ Clinical Game-Changers:
• Prediabetes → normal glucose: 72% (vs 22% placebo)
• BP medication discontinued: 41% (8mg), 30% (12mg)
• HbA1c reduction: -2.02% (12mg)
• Systolic BP: ↓10.2 mmHg
• Triglycerides: ↓37%

Safety: Primarily GI effects (dose-dependent). Serious AEs similar to placebo.

Bio Next Gen™ Product Specifications

Manufacturing Excellence

text
🏭 What You Get From Bio Next Gen™:
✅ 99%+ HPLC purity (CoA certified)
✅ Lyophilized powder (medical-grade vials)
✅ USA synthesis standards
✅ Sequential fingerprint verification
✅ LC-MS/MS molecular confirmation
✅ Residual moisture <1%

Research Applications

text
🔬 Perfect For:
• Obesity pharmacodynamics
• Triple receptor agonist studies  
• Diabetic kidney disease models
• Gut microbiota modulation
• Cardiometabolic intervention
• Long-term weight management